{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:08:22Z","timestamp":1768255702240,"version":"3.49.0"},"reference-count":37,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T00:00:00Z","timestamp":1555804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Omadacycline (Nuzyra\u00ae) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria.<\/jats:p>","DOI":"10.3390\/ph12020063","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T11:02:53Z","timestamp":1555930973000},"page":"63","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4201-2774","authenticated-orcid":false,"given":"Fernando","family":"Dur\u00e3es","sequence":"first","affiliation":[{"name":"Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"},{"name":"CIIMAR, Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leix\u00f5es, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-4672","authenticated-orcid":false,"given":"Em\u00edlia","family":"Sousa","sequence":"additional","affiliation":[{"name":"Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"},{"name":"CIIMAR, Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Terminal de Cruzeiros do Porto de Leix\u00f5es, Avenida General Norton de Matos P, 4450-208 Matosinhos, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fmicb.2010.00134","article-title":"A brief history of the antibiotic era: Lessons learned and challenges for the future","volume":"1","author":"Aminov","year":"2010","journal-title":"Front. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.2174\/0929867325666180209142612","article-title":"Medicinal chemistry updates on bacterial efflux pump modulators","volume":"25","author":"Duraes","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_3","unstructured":"US Food and Drug Administration (2019, February 24). Novel Drug Approvals for 2018, Available online: https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/druginnovation\/ucm592464.htm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/1060028018818094","article-title":"Omadacycline: A new tetracycline antibiotic","volume":"53","author":"Dougherty","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/QCO.0000000000000526","article-title":"New antibiotics for community-acquired pneumonia","volume":"32","author":"Kollef","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"Green","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMe1900188","article-title":"Omadacycline\u2014The newest tetracycline","volume":"380","author":"Chambers","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QCO.0000000000000429","article-title":"The role of omadacycline in skin and soft tissue infections","volume":"31","author":"Montravers","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s40265-018-1015-2","article-title":"Omadacycline: First global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Watkins, R.R., and Deresinski, S. (2019). Omadacycline: A novel tetracycline derivative with oral and intravenous formulations. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.","DOI":"10.1093\/cid\/ciz242"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1128\/AAC.01536-15","article-title":"Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline","volume":"59","author":"Honeyman","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","article-title":"Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic","volume":"24","author":"Tanaka","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"Draper","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1358\/dot.2018.54.3.2800620","article-title":"Return of the tetracyclines: Omadacycline, a novel aminomethylcycline antimicrobial","volume":"54","author":"Cho","year":"2018","journal-title":"Drugs Today"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Heidrich, C.G., Mitova, S., Schedlbauer, A., Connell, S.R., Fucini, P., Steenbergen, J.N., and Berens, C. (2016). The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline-binding site on the bacterial ribosome. Antibiotics, 5.","DOI":"10.3390\/antibiotics5040032"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3389\/fmicb.2018.01058","article-title":"Tetracycline-inactivating enzymes","volume":"9","author":"Markley","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/acsinfecdis.8b00349","article-title":"Semisynthetic analogues of anhydrotetracycline as inhibitors of tetracycline destructase enzymes","volume":"5","author":"Markley","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: Development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/phar.2185","article-title":"Omadacycline enters the ring: A new antimicrobial contender","volume":"38","author":"Barber","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_22","unstructured":"Traczewski, M.M., and Brown, S.D. (2003, January 14\u201317). PTK 0796 (BAY 73-6944): In vitro potency and spectrum of activity compared to ten other antimicrobial compounds. Proceedings of the 43rd Interscience Congress on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2018.11.010","article-title":"Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants","volume":"94","author":"Fluit","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_24","first-page":"e01907","article-title":"In vitro activity of omadacycline against Chlamydia pneumoniae","volume":"63","author":"Kohlhoff","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e02327-17","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the united states and europe as part of the 2016 SENTRY antimicrobial surveillance program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00047-18","DOI":"10.1128\/AAC.00047-18","article-title":"In vitro activities of omadacycline and comparators against anaerobic bacteria","volume":"62","author":"Stapert","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.32607\/20758251-2016-8-2-24-34","article-title":"Mycoplasmas and their antibiotic resistance: The problems and prospects in controlling infections","volume":"8","author":"Chernova","year":"2016","journal-title":"Acta Nat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3201\/eid2108.150273","article-title":"Macrolide-resistant Mycoplasma pneumoniae, United States","volume":"21","author":"Xiaotian","year":"2015","journal-title":"Emerg. Infect. Dis. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1128\/AAC.01734-16","article-title":"In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"60","author":"Waites","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Horn, K., Gotfried, M.H., Steenbergen, J., Villano, S., Tzanis, E., Garrity-Ryan, L., Chitra, S., Manley, A., Tanaka, K., and Rodvold, K. (2017, January 22\u201325). Comparison of omadacycline (OMC) and tigecycline (TGC) pharmacodynamics (PD) in the plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) in healthy subjects. Proceedings of the 27th European Congress Clinical Microbiology and Infectious Diseases, Vienna, Austria.","DOI":"10.1128\/AAC.01135-17"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Shoen, C., Benaroch, D., Sklaney, M., and Cynamon, M. (2019). In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.02522-18"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1128\/AAC.00948-12","article-title":"A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections","volume":"56","author":"Noel","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/ofid\/ofy210.1178","article-title":"1347. Omadacycline for acute bacterial skin and skin structure infections: Integrated analysis of randomized clinical trials","volume":"5","author":"Abrahamian","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_35","unstructured":"ClinicalTrials.gov (2019, March 08). Oral Omadacycline Vs. Oral Nitrofurantoin for the Treatment of Cystitis, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03425396?term=omadacycline&rank=3."},{"key":"ref_36","unstructured":"ClinicalTrials.gov (2019, March 08). Iv or iv\/po omadacycline vs. Iv\/po levofloxacin for the treatment of acute pyelonephritis, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03757234?term=omadacycline&rank=1."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Overcash, J.S., Bhiwandi, P., Garrity-Ryan, L., Steenbergen, J., Bai, S., Chitra, S., Manley, A., and Tzanis, E. (2019). Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: Results from a phase 1 study. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.02083-18"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/2\/63\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:46:06Z","timestamp":1760186766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/2\/63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,21]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ph12020063"],"URL":"https:\/\/doi.org\/10.3390\/ph12020063","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,21]]}}}